Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various national committee for clinical laboratory standards susceptibility test methods
- 31 May 1994
- journal article
- guideline
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 19 (1) , 65-68
- https://doi.org/10.1016/0732-8893(94)90054-x
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroximeAntimicrobial Agents and Chemotherapy, 1993
- Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1993
- Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolatesAntimicrobial Agents and Chemotherapy, 1992
- In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolonesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1992
- In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacinAntimicrobial Agents and Chemotherapy, 1992
- Statistical criteria for selecting quality control limits for broth microdilution susceptibility tests with 39 different antimicrobial agentsPublished by Elsevier ,1989